When Merck purchased OncoImmune to gain control of the experimental treatment for COVID-19, and shortly after signed a $356 million dollar government contract to deliver 100,000 doses by the summer, it was assumed that Merck would be able to deliver. However, despite positive trial data, the FDA is demanding that there be more evidence of the drug’s effect before it can be rolled out on such a massive scale.
It’s already had to give up on any hopes of creating a vaccine against COVID-19, and now Merck is being told that its pandemic drug hopeful will need another trial before it can be issued a green light.
MVG Consulting Services specializes in helping small to medium sized biotechnology and pharmaceutical companies with their clinical development programs and we can provide start-up and virtual companies with the necessary resources to begin their clinical development program.
Services include:
- Clinical Research Consulting Services
- Clinical Trial Development
- Project Rescue
- Inspection Readiness
MVG provides highly qualified clinical research professionals who seamlessly become a part of your project team. Additionally, we provide virtual companies with an entire project team that encompasses all aspects of clinical development.
We invite you to fill out the form below to learn more about how MVG Consulting can help you with your clinical devleopment needs.
